These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16998874)

  • 21. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
    Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
    J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin.
    Smallshaw JE; Richardson JA; Pincus S; Schindler J; Vitetta ES
    Vaccine; 2005 Sep; 23(39):4775-84. PubMed ID: 15961194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of single-point mutations on the stability and immunogenicity of a recombinant ricin A chain subunit vaccine antigen.
    Thomas JC; O'Hara JM; Hu L; Gao FP; Joshi SB; Volkin DB; Brey RN; Fang J; Karanicolas J; Mantis NJ; Middaugh CR
    Hum Vaccin Immunother; 2013 Apr; 9(4):744-52. PubMed ID: 23563512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine.
    Vitetta ES; Smallshaw JE; Schindler J
    Clin Vaccine Immunol; 2012 Oct; 19(10):1697-9. PubMed ID: 22914366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural perturbation of diphtheria toxoid upon adsorption to aluminium hydroxide adjuvant.
    Régnier M; Metz B; Tilstra W; Hendriksen C; Jiskoot W; Norde W; Kersten G
    Vaccine; 2012 Nov; 30(48):6783-8. PubMed ID: 23000120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. H1N1 influenza virus-like particles: physical degradation pathways and identification of stabilizers.
    Kissmann J; Joshi SB; Haynes JR; Dokken L; Richardson C; Middaugh CR
    J Pharm Sci; 2011 Feb; 100(2):634-45. PubMed ID: 20669328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulation of botulinum neurotoxin heavy chain fragments for vaccine development: mechanisms of adsorption to an aluminum-containing adjuvant.
    DePaz RA; Henderson I; Advant SJ
    Vaccine; 2005 Jul; 23(31):4029-35. PubMed ID: 15963360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of vaccine stability.
    Volkin DB; Burke CJ; Sanyal G; Middaugh CR
    Dev Biol Stand; 1996; 87():135-42. PubMed ID: 8854010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of intranasal vaccination with recombinant chain A ricin vaccine (rRV) in mice by the mucosal adjuvants LTK63 and LTR72.
    Kende M; Tan X; Wlazlowski C; Williams R; Lindsey C; Del Giudice G
    Vaccine; 2007 Apr; 25(16):3219-27. PubMed ID: 17343960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice.
    O'Hara JM; Brey RN; Mantis NJ
    Clin Vaccine Immunol; 2013 Jun; 20(6):789-94. PubMed ID: 23515013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction and physiochemical characterisation of a multi-composite, potential oral vaccine delivery system (VDS).
    Pettit MW; Dyer PD; Mitchell JC; Griffiths PC; Alexander B; Cattoz B; Heenan RK; King SM; Schweins R; Pullen F; Wicks SR; Richardson SC
    Int J Pharm; 2014 Jul; 468(1-2):264-71. PubMed ID: 24680960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preformulation study of highly purified inactivated polio vaccine, serotype 3.
    Qi W; Zeng Y; Orgel S; Francon A; Kim JH; Randolph TW; Carpenter JF; Middaugh CR
    J Pharm Sci; 2014 Jan; 103(1):140-51. PubMed ID: 24282078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal vaccine.
    Hu L; Joshi SB; Liyanage MR; Pansalawatta M; Alderson MR; Tate A; Robertson G; Maisonneuve J; Volkin DB; Middaugh CR
    J Pharm Sci; 2013 Feb; 102(2):387-400. PubMed ID: 23161162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of adsorption of three recombinant Streptococcus pneumoniae (Sp) vaccine antigens by an aluminum adjuvant.
    Levesque PM; de Alwis U
    Hum Vaccin; 2005; 1(2):70-3. PubMed ID: 17038824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An intrinsic fluorescence method for the determination of protein concentration in vaccines containing aluminum salt adjuvants.
    Nouchikian L; Roque C; Song JY; Rahman N; Ausar SF
    Vaccine; 2018 Sep; 36(38):5738-5746. PubMed ID: 30107994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.
    Little SF; Ivins BE; Webster WM; Norris SL; Andrews GP
    Vaccine; 2007 Apr; 25(15):2771-7. PubMed ID: 17240008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors affecting alum-protein interactions.
    Huang M; Wang W
    Int J Pharm; 2014 May; 466(1-2):139-46. PubMed ID: 24607202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel oil-in-water emulsion as a potential adjuvant for influenza vaccine: development, characterization, stability and in vivo evaluation.
    Deng J; Cai W; Jin F
    Int J Pharm; 2014 Jul; 468(1-2):187-95. PubMed ID: 24704309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody.
    Wakankar AA; Liu J; Vandervelde D; Wang YJ; Shire SJ; Borchardt RT
    J Pharm Sci; 2007 Jul; 96(7):1708-18. PubMed ID: 17238195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel recombinant vaccine which protects mice against ricin intoxication.
    Smallshaw JE; Firan A; Fulmer JR; Ruback SL; Ghetie V; Vitetta ES
    Vaccine; 2002 Sep; 20(27-28):3422-7. PubMed ID: 12213413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.